<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>, a class III antiarrhythmic agent, shows ÃŸ blocker-like and <z:chebi fb="0" ids="50509">potassium channel blocker</z:chebi>-like actions on the sinuatrial and atrioventricular nodes </plain></SENT>
<SENT sid="1" pm="."><plain>It is given by mouth in the treatment of <z:hpo ids='HP_0000001'>all</z:hpo> forms of atrial, junctional and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Capsules for paediatric patients are not commercially available and must be prepared in the pharmacy department </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of the study was to evaluate the stability of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> at different dosages, 10, 60 and 100 mg, in capsules for paediatric patients stored in three packages under dark conditions and at room temperatures over one year </plain></SENT>
<SENT sid="4" pm="."><plain>At different intervals during the storage period, <z:chebi fb="0" ids="2663">amiodarone</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> concentration was tested using a high-performance liquid chromatography (HPLC) method </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> content remained greater than 95% of the initial concentration in <z:hpo ids='HP_0000001'>all</z:hpo> capsules at <z:hpo ids='HP_0000001'>all</z:hpo> dosages </plain></SENT>
<SENT sid="6" pm="."><plain>The 10, 60 and 100 mg <z:chebi fb="0" ids="2663">amiodarone</z:chebi> paediatric capsules were stable for one year when stored in the three packages at ambient temperature and under dark conditions </plain></SENT>
</text></document>